Ionis Pharmaceuticals (IONS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ionis Pharmaceuticals (IONS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.6B, trading at $52.29 on the NASDAQ. This SniperIQ fundamentals page covers Ionis Pharmaceuticals's valuation, profitability (net margin -30.9%), revenue ($944M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ionis Pharmaceuticals's market cap?
Ionis Pharmaceuticals (IONS) has a market capitalization of approximately $8.6B, trading at $52.29 on the NASDAQ. Market cap moves with the live share price.
What is Ionis Pharmaceuticals's P/E ratio?
Ionis Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 17.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ionis Pharmaceuticals?
Ionis Pharmaceuticals runs a net profit margin of -30.9%, a gross margin of 98.3%, and an operating margin of -33.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ionis Pharmaceuticals generate?
Ionis Pharmaceuticals reported revenue of $944M for fiscal year 2025, with net income of -